Table 2 Results of the systematic literature review regarding clinical benefits
Authors | Title | Year | Journal | Intervention | Median OS |
|---|---|---|---|---|---|
Crump et al. [22] | Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study | 2017 | Blood | BSC | 6.3 months |
Dreger et al. [23] | CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison | 2020 | Blood Advances | alloSCT | 7.4 monthsa |
Sesques et al. [24] | Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center | 2020 | American Journal of Hematology | CAR T | 11.8 months (tisa-cel) not reached (axi-cel) |
Dean et al. [26] | High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma | 2020 | Blood Advances | CAR T | 34 months (axi-cel) |
Schuster et al. [25] | Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | 2019 | New England Journal of Medicine | CAR T | 12 months (tisa-cel) |
Mian et al. [27] | Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis | 2020 | Leukemia & Lymphoma | CAR T | 13 months (axi-cel) |